Long-acting lenacapavir in people with multi-drug resistant HIV-1: week 52 results

被引：0
|
作者：
Ogbuagu, Onyema [1 ]
Segal-Maurer, Sorana [2 ]
Brinson, Cynthia [3 ]
Chetchotisakd, Ploenchan [4 ]
McGowan, Joseph P. [5 ]
Workowski, Kimberly [6 ]
Wang, Hui [7 ]
Margot, Nicolas [7 ]
Dvory-Sobol, Hadas [7 ]
Rhee, Martin S. [7 ]
Baeten, Jared [7 ]
Kabagambe, Samm [8 ]
Molina, Jean-Michel [9 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] New York Presbyterian Queens, Flushing, NY USA
[3] Cent Texas Clin Res, Austin, TX USA
[4] Srinagarind Hosp, Khon Kaen, Thailand
[5] North Shore Univ Hosp, Manhasset, NY USA
[6] Emory Univ, Atlanta, GA 30322 USA
[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] Gilead Sci Ltd, London, England
[9] Hop St Louis, Paris, France
来源：
HIV MEDICINE | 2022年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P006
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [41] Unique response of tipranavir to multi-drug resistant HIV-1 proteases suggests new ways of combating drug resistance
    Muzammil, S
    Kong, LW
    Armstrong, AA
    Jakalian, A
    Bonneau, PR
    Schmelmer, V
    Amzel, LM
    Freire, E
    [J]. ANTIVIRAL THERAPY, 2005, 10 (04) : S70 - S70
  • [42] Unique response of tipranavir to multi-drug resistant HIV-1 proteases suggests new ways of combating drug resistance
    Muzammil, S
    Kang, LW
    Armstrong, AA
    Jakalian, A
    Bonneau, PR
    Schmelmer, V
    Amzel, LM
    Freire, E
    [J]. ANTIVIRAL THERAPY, 2005, 10 : S70 - S70
  • [43] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
    Orkin, Chloe O. C.
    Arasteh, Keikawus A. K.
    Hernandez-Mora, M. Gorgolas M. G. H. M.
    Pokrovsky, Vadim P. V.
    Overton, Edgar T. O. E. T.
    Girard, Pierre-Marie G. P. M.
    Oka, Shinichi O. S.
    Walmsley, Sharon W. S.
    Bettacchi, Chris B. C.
    Brinson, Cynthia B. C.
    Philibert, Patrick P. P.
    Lombaard, Johan L. J.
    Clair, Marty C. M.
    Crauwels, Herta C. H.
    Ford, Susan L. F. S. L.
    Patel, Parul P. P.
    Chounta, Vasiliki C. V.
    D'Amico, Ronald D. R.
    Vanveggel, Simon V. S.
    Dorey, David D. D.
    Cutrell, Amy C. A.
    Griffith, Sandy G. S.
    Margolis, David A. M. D. A.
    Williams, Peter E. W. P. E.
    Parys, Wim P. W.
    Smith, Kimberly Y. S. K. Y.
    Spreen, William R. S. W. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
  • [44] Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine
    Audelin, Anne Margrethe
    Lebech, Anne-Mette
    Petersen, Ann Berith
    Jorgensen, Louise Bruun
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (08) : 1319 - 1321
  • [45] Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
    Singh, Kamal
    Sarafianos, Stefan G.
    Sonnerborg, Anders
    [J]. PHARMACEUTICALS, 2019, 12 (02)
  • [46] Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
    Ogbuagu, Onyema
    Segal-Maurer, Sorana
    Ratanasuwan, Winai
    Avihingsanon, Anchalee
    Brinson, Cynthia
    Workowski, Kimberly
    Antinori, Andrea
    Yazdanpanah, Yazdan
    Trottier, Benoit
    Wang, Hui
    Margot, Nicolas
    Dvory-Sobol, Hadas
    Rhee, Martin S.
    Baeten, Jared M.
    [J]. LANCET HIV, 2023, 10 (08): : E497 - E505
  • [47] Structural basis of unprecedented potency of GRL-142 against multi-drug resistant HIV-1 protease
    Das, Debananda
    Aoki, Manabu
    Hayashi, Hironori
    Takamatsu, Yuki
    Bulut, Haydar
    Yedidi, Ravikiran
    Rao, Kalapala
    Ghosh, Arun
    Mitsuya, Hiroaki
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [48] Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy
    D'Amico, Ronald
    Gomis, Santiago Cenoz
    Moodley, Riya
    Van Solingen-Ristea, Rodica
    Baugh, Bryan
    Van Landuyt, Erika
    Van Eygen, Veerle
    Min, Sherene
    Cutrell, Amy
    Foster, Caroline
    Chilton, Daniella
    Allard, Sabine D.
    Ruiter, Annemiek
    [J]. HIV MEDICINE, 2023, 24 (02) : 202 - 211
  • [49] LONG-TERM OUTCOMES OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV VIA A COST-EFFECTIVENESS MODEL
    Vardanega, V.
    Rawlinson, W.
    Francis-Graham, S.
    Mezzio, D.
    Eddowes, L. A.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S379 - S379
  • [50] Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent
    Subramanian, Raju
    Tang, Jennifer
    Zheng, Jim
    Lu, Bing
    Wang, Kelly
    Yant, Stephen R.
    Stepan, George J.
    Mulato, Andrew
    Yu, Helen
    Schroeder, Scott
    Shaik, Naveed
    Singh, Renu
    Wolckenhauer, Scott
    Chester, Anne
    Tse, Winston C.
    Chiu, Anna
    Rhee, Martin
    Cihlar, Tomas
    Rowe, William
    Smith, Bill J.
    [J]. MOLECULAR PHARMACEUTICS, 2023, 20 (12) : 6213 - 6225
12345